Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.
about
The CHRNA5-A3-B4 Gene Cluster and Smoking: From Discovery to TherapeuticsPathways to precision medicine in smoking cessation treatments.Pharmacogenetic Optimization of Smoking Cessation Treatment.Leveraging genomic data in smoking cessation trials in the era of Precision Medicine: Why and how.Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-AnalysisGenetic susceptibility variants for lung cancer: replication study and assessment as expression quantitative trait loci.Oral Cell DNA Adducts as Potential Biomarkers for Lung Cancer Susceptibility in Cigarette Smokers.The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings.Innovative approaches to support smoking cessation for individuals with mental illness and co-occurring substance use disorders.Increased nicotine response in iPSC-derived human neurons carrying the CHRNA5 N398 allele.A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy.Tobacco use disorder and treatment: new challenges and opportunities.Preparing the Way: Exploiting Genomic Medicine to Stop Smoking.Toward the implementation of genomic applications for smoking cessation and smoking-related diseases.Association of the DBH Polymorphism rs3025343 With Smoking Cessation in a Large Population-Based Sample.Cholinergic receptor nicotinic alpha 5 subunit polymorphisms are associated with smoking cessation success in women.
P2860
Q28072077-62AC30C1-3C5D-426C-896D-C3C482DC6C08Q34527740-91C0CAAA-064B-4598-B117-4144078DD53FQ34542169-F6505BA2-D497-4BF0-B4E3-C00A96A56FB8Q36370325-53436867-8D13-4040-9C2A-D4F1B6CE12EAQ37309498-47206921-3735-45BB-9E30-848FBECF3FC8Q37633874-0C03813D-750A-4E2E-8693-8342A12422D2Q37643215-6F6E2CBC-CF71-4980-BC65-6DFCCA23E3BBQ39284073-3EB031AD-D5D5-4D89-B012-2EEBAA83A873Q40102553-51981D74-C10C-4533-B6C8-1386A17A0D56Q41290146-604F0327-B57C-4E32-868C-286B74097300Q45040238-27F857F7-9B6C-4C52-BACA-8E8F83E60D1EQ47130262-93E72C07-BA7A-4163-B251-1AB60D984060Q47200916-CFAF87BD-D893-4923-920E-92D03AD8BFFFQ47551037-F2059BD4-D463-4C5E-BCC5-E20CC6C48959Q47926506-4B7BCBCE-29CF-458F-9577-3E23232B4D7DQ55039412-EAFDB5E9-0AA6-49C2-8CA3-DB3851A37F58
P2860
Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Genetic variation (CHRNA5), me ...... cline), and smoking cessation.
@ast
Genetic variation (CHRNA5), me ...... cline), and smoking cessation.
@en
type
label
Genetic variation (CHRNA5), me ...... cline), and smoking cessation.
@ast
Genetic variation (CHRNA5), me ...... cline), and smoking cessation.
@en
prefLabel
Genetic variation (CHRNA5), me ...... cline), and smoking cessation.
@ast
Genetic variation (CHRNA5), me ...... cline), and smoking cessation.
@en
P2093
P2860
P1476
Genetic variation (CHRNA5), me ...... cline), and smoking cessation.
@en
P2093
Douglas Jorenby
Eric Johnson
Li-Shiun Chen
Megan Piper
Nancy Saccone
Naomi Breslau
Robert M Carney
Timothy B Baker
P2860
P304
P356
10.1016/J.DRUGALCDEP.2015.06.022
P577
2015-06-23T00:00:00Z